Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × olaparib × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 16 Fallopian Tube Neoplasms 12 Breast Neoplasms 8 Triple Negative Breast Neoplasms 7 Endometrial Neoplasms 4 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Metastatic Castration-resistant Prostate Cancer 2 Glioma 2 Glioblastoma 2 Carcinoma 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Sarcoma 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer, Hereditary, 7 1 Pheochromocytoma 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Paraganglioma 1 Ovarian Neoplasm Epithelial 1 Osteosarcoma 1 Multiple Myeloma 1 Metastatic Castration-Resistant Prostate Cancer 1

Interventions

Specimen Handling 5 Cyclophosphamide 5 Radiotherapy 4 Biopsy 4 X-Rays 3 Trabectedin 3 Magnetic Resonance Spectroscopy 3 regorafenib 2 pembrolizumab 2 pazopanib 2 fludarabine 2 atezolizumab 2 Radiation 2 Phantoms, Imaging 2 Ifosfamide 2 Gemcitabine 2 Etoposide 2 Doxorubicin 2 trastuzumab deruxtecan 1 tivozanib 1 tazemetostat 1 talimogene laherparepvec 1 selinexor 1 pimonidazole 1 perflutren 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 olaparib 1 fluoroazomycin arabinoside 1 fludarabine phosphate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02787642 2026-02-25

RADIOSARP

Institut Bergonié

Phase 1 Completed

41 enrolled 15 charts

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡